Recent Updates — ENHA

Enhanced Group Inc. expects to effect a one-for-ten reverse stock split of its Class A and Class B common stock, combining ten shares into one share per class. The transaction is scheduled to become effective at 12:01 a.m. Central Time on October 29, 2026, with split-adjusted trading expected to begin that day under the existing symbol ENHA on the New York Stock Exchange. The company states the split will not alter par value, authorized share counts, or shareholder ownership percentages, except for rounding of fractional shares which will be rounded up to the nearest whole share. Proportionate adjustments will apply to outstanding equity awards and warrants. Enhanced Group Inc. operates in the construction industry, providing general contracting services.

Enhanced Group Inc. announced the resignation of directors James J. Murren and Christian Angermayer from its Board of Directors, effective September 17, 2026. Mr. Murren also stepped down as Chair of the Audit Committee, while Mr. Angermayer resigned as Chairman of the Board. Both departures were not due to disagreements with company operations. The Board appointed Michael Sepso, a veteran esports executive and Co-Founder of Major League Gaming, as a new director and Audit Committee member. James Simpson was named Chairman of the Board, and Anthony D. Eisenberg became Chair of the Audit Committee. Mr. Sepso received an initial RSU award valued at $370,000 and an annual cash retainer of $50,000. The company operates in the elite sports competition and performance products industry.

Enhanced Group Inc. reported financial results for the quarter ended June 30, 2026, generating $17.7 million in revenue primarily from sponsorship deals for its inaugural Enhanced Games. The company secured approximately $32 million in total sponsorship contract value and raised an additional $50 million in PIPE financing, with further tranches expected to close shortly. Despite top-line growth, the firm reported a net loss of $61.9 million and an adjusted EBITDA loss of $42.7 million, driven by significant costs associated with staging the Games, clinical trials, and operating as a public company. Cash and cash equivalents stood at $19.6 million as of June 30, 2026. The company operates in the performance medicine and sports entertainment industry.